Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032106 · ClinicalTrials.gov registry record · NA
HPV Vaccine Intervention for Young Sexual Minority Men
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,227
- Enrollment target
NCT04032106: Completed NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT04032106 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 1,227 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04032106, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,227 participants
- Enrollment target
Study Summary
This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, being sexually attracted to males, or identify as gay, bisexual, or queer (i.e., sexual minority males). The Outsmart HPV intervention, which is a population-targeted, individually-tailored mHealth intervention that includes vaccine reminders, may increase HPV vaccine initiation and completion among unvaccinated young sexual minority individuals.
Primary Outcome
Number and proportion of participants who initiate and complete the HPV vaccine series during the study period
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Informational Intervention
- BEHAVIORAL Text Message-Based Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,227 participants |
| Start Date | 2019-10-03 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT04032106 record still lists
NCT04032106 is an interventional study that assigns participants to a tested intervention. Its 1,227 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT04032106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04032106 about?
NCT04032106 is a clinical study titled "HPV Vaccine Intervention for Young Sexual Minority Men". This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, being sexually attracted to males, or identify as gay, bisexual, or queer (i.e., sexual minority mal...
What is the current status of trial NCT04032106?
This trial is currently completed. It is a NA study. The enrollment target is 1,227 participants. The study started on 2019-10-03. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04032106?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Informational Intervention (OTHER), Text Message-Based Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04032106?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04032106's enrollment target sits among peer trials
1,227 83rd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI